和邦生物(603077.SH):擬投資125億元建50萬噸/年雙甘膦生產線
格隆匯4月18日丨 和邦生物(603077.SH)公佈,公司目前是高技術綠色專用中間體雙甘膦全球最大的供應商,基於公司“專注、專業、做優、做強”的高質量發展戰略,公司於2022年4月18日與廣安市人民政府及廣安經濟技術開發區管理委員會分別簽訂了《廣安市人民政府四川和邦生物科技股份有限公司合作協議》、《廣安經濟技術開發區管理委員會四川和邦生物科技股份有限公司高技術綠色專用中間體項目投資協議》,擬建設50萬噸/年雙甘膦生產線,建設內容及規模以可研和設計為準,項目總投資約125億元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.